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Submitted Jan 18, 2014; accepted May 16, 2014.DISCUSSIONDr Eugene M. Langan III (Greenville, SC). This is an inter-
esting paper from the Division of Cardiovascular and Thoracic
Surgery at Duke University. The premise of this study is that for
selected patients undergoing thoracic endovascular aortic repair
(TEVAR), preoperative cardiac workup can be limited to a history
and physical, electrocardiography, and transthoracic echocardiog-
raphy. The study’s primary end point was deﬁned as myocardial
infarction or cardiac arrest, interestingly not death.
Their results reveal a myocardial infarction or cardiac arrest
rate of 2.4% or nine of 380 patients. There were 21 or 5.5%
patient deaths within 30 days or within the hospital stay. Three
of the deaths were cardiac in etiology.
I have three questions for the authors:
1. It would seem to me that the type of anesthesia used would
affect the perioperative stress levels and therefore potential
cardiac risk to the patient, yet you do not include anything
about the type of anesthesia. Can you please comment on this?
2. I understand that death was not part of this study’s end point,
but can you still comment on the other 18 noncardiac deaths?
3. In the manuscript, you suggest a limited cardiac workup
to avoid delay of surgical repair but then recommend 30-day
preoperative statin therapy. This does not make sense. Please
explain.
I would like to thank the Association for the privilege of the
ﬂoor and allowing me to open this discussion.
Dr Asvin M. Ganapathi. Regarding the ﬁrst question, all
patients in this study underwent general anesthesia under the
oversight of a cardiothoracic specialty-trained anesthesiologist.We believe that general anesthesia is useful in these patients as it
eliminates problems with patient movement and allows accurate
and precise delivery of the stent grafts. We do not use local anes-
thesia for any TEVAR procedures, and all TEVAR procedures at
Duke are done in a hybrid operating room with cardiac anesthesi-
ology, intraoperative transesophageal echocardiographic moni-
toring, and general anesthesia. We believe that this approach is
safe on the basis of the low incidence of perioperative cardiac
events detailed in this study.
With regard to the second question about the non-cardiac-
related deaths, of the 18 noncardiac deaths, there were multiple
causes. The primary cause of death after TEVAR was perioperative
complications related to patient comorbidities or the underlying
aortic disease process.
Finally, concerning the third question, in the manuscript we
mention the use of preoperative statin therapy; however, we are
not suggesting that every patient be prescribed 30 days of statin
therapy preoperatively before proceeding with TEVAR. Rather,
we mention this as it has been detailed in the literature as a known
therapy with the potential to reduce perioperative cardiac
morbidity and mortality. For elective cases in which the patient
is not already receiving a statin, we generally will initiate statin
therapy at the time the patient is evaluated in the outpatient
setting; however, we will not do this at the cost of delaying
surgery. In addition, for nonelective cases, the limited cardiac
workup protocol is employed if the patient is stable. We do not
advocate for delay of surgery to initiate medical therapy in the
nonelective scenario.
